06/16/2026
NeOnc Technologies is pleased to announce that the Department of Health – Abu Dhabi has granted IND status for NEO212, our orally administered perillyl alcohol-temozolomide conjugate being developed for patients with aggressive brain tumors.
This milestone follows the successful completion of the Phase 1 dose-escalation portion of the NEO212 clinical program.
The UAE clearance marks an important international step as NeOnc advances NEO212 toward Phase 2 development, while continuing discussions with the U.S. FDA.
Read the full press release in our Investor highlight.